| Dendreon's Dip Creates a Great Opportunity VFC submits: Shares of Dendreon (DNDN) dropped to under thirty seven dollars on Monday morning, closing the day ten percent to the downside at $36.70. A dip in the DNDN share price had been expected by some during the time between the FDA's announcement of Provenge approval and the commercial launch of the product, but Monday's drop may also have been the result of an 'honest mistake' by CNBC who had reported that the supply of Provenge outweighed the current demand. CNBC corrected their mistake later in the day, stating that, in actuality, the demand for Provenge outweighed the supply. By then, however, the damage had been done and the DNDN stock embarked on a 10% downward spiral for the day.Speculation was rampant around the Internet and in the blogosphere that CNBC's 'mistake' was not quite an honest one, but one intended to help out some Wall Street buddies looking to build on their positions for lower prices. CNBC's already suspect track record of honest reporting - including Jim Cramer's questionable tactics - only add fuel to the fire. Complete Story » seekingalpha.com |
His Honor's Fitness Secret: Treads and Risers In What's Your Workout?, Denver mayor John Hickenlooper encourages a "stairs only" approach to fitness for himself and municipal employees. online.wsj.com |
BioClinica to Demonstrate Global Technology-Enhanced Trial Service Capabilities at Leading Industry Events (Business Wire) NEWTOWN, Pa.----BioClinicaâ„¢, Inc. , a global provider of clinical trial management services, will attend and speak at several key industry conferences throughout the third and fourth quarters of 2010. us.rd.yahoo.com |
Keryx Remains a Focused, Well-Funded Bio-Pharma Play Mike Havrilla submits:Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) is an emerging, small-cap biopharma company that has a pair of lead compounds in late-stage, Phase 3 development for the treatment of cancer (perifosine) and renal disease (Zerenex) under Special Protocol Assessment (SPA) agreements with the FDA. I initially wrote about KERX in January 2010, and the Company has performed well (with stock price doubling from approx. $2.50 to $5.00 per share) thanks to delivering on its strategic objectives of advancing its lead compounds into three pivotal Phase 3 studies - with Phase 3 results expected for Zerenex in about three months (December timeframe). KERX is well capitalized with no debt/convertibles and approximately $32 million in cash/equivalents as of 6/30/10. In addition, the Company has about 59 million shares of common stock outstanding with a fully diluted share count of 70 million and average daily trading volume that has grown over the past year to over 1 million shares per day. The expected cash burn rate for KERX during 2H10 is approximately $10 million, which will be offset by the same amount in expected milestone payments over the next six months that include option/warrant exercises and a milestone payment from its Zerenex partner in Japan (JT Torii) upon initiation of a pivotal Phase 3 study.Complete Story » seekingalpha.com |
Near-Term Uncertainty Makes SIGA Technologies a Low-Risk Buy Above Average Odds Investing submits: The investment analysis below is our ninth in our ongoing series of guest write-ups, and is brought to you by a friend of the blog, Ryan Morris. Ryan is managing partner at Meson Capital, a focused, value oriented hedge fund based out of New York/Toronto (we would note that Ryan is also a Contributor at Sum Zero, a member of both VIC and DDIC, as well as the newest "value voice" at the fantastic CGI Value). Meson was formed in February 2009 and has returned north of 400% net to partners since its inception (for what it's worth, we actually had to rub our eyes a bit the first time we saw it. Incredible no?). Anyhow, we found Ryan's write-up on current AAOI Partners Fund holding SIGA Technologies (SIGA) to be not only cogent and concise, but particularly timely given the company's recent developments and the minimal reaction to what was undoubtedly a game changing event for the company and its future.Complete Story » seekingalpha.com |